In 2026, one of the most alarming product liability cases in recent memory continues to unfold across courtrooms nationwide. The contaminated eye drops lawsuit involving EzriCare Artificial Tears has reached a critical phase, with several injury and class action lawsuits already filed and important deadlines fast approaching. If you or someone you love used EzriCare or Delsam Pharma artificial tears and experienced a serious eye infection, vision loss, or worse, what happens in the coming months could directly affect your ability to recover compensation. Here is everything injured victims need to know right now.
What Happened: The EzriCare Contamination Crisis
The crisis began when the U.S. Food and Drug Administration issued a sweeping recall of EzriCare Artificial Tears and Delsam Pharma Artificial Tears — the culmination of an investigation into products manufactured by Global Pharma Healthcare, an India-based company. Laboratory testing confirmed the presence of Pseudomonas aeruginosa, specifically a carbapenem-resistant strain known as CRPA, one of the most dangerous and drug-resistant bacteria that can infect the human eye.
The contamination was not a minor quality-control lapse. According to the Centers for Disease Control and Prevention, investigators identified 81 infections spanning 18 states, resulting in at least 4 deaths and 4 cases requiring surgical eye removal — a procedure known medically as enucleation. These are not statistics. These are real people who trusted an over-the-counter product to soothe dry eyes and instead suffered life-altering or fatal consequences.
The lawsuits that followed allege that Global Pharma Healthcare, as well as distributors and retailers who sold the product, engaged in negligent manufacturing practices, failed to adequately test for contamination, and violated FDA Current Good Manufacturing Practice (CGMP) regulations — including the use of multi-dose bottles without preservatives, a practice that significantly increases bacterial contamination risk. The broader contaminated eye drops landscape has also expanded in 2026: in early 2026, the FDA flagged a major recall of more than 3.1 million bottles of eye drops by K.C. Pharmaceuticals due to lack of sterility assurance, underscoring that the EzriCare crisis is part of a wider pattern of manufacturing failures in the eye drop industry.
Documented Injuries: What the FDA and CDC Data Reveals
The scope of harm tied to this product is severe, and the documented injury profile is central to understanding why this litigation carries such significant compensation potential. Victims have reported a wide spectrum of injuries, ranging from painful corneal ulcers to permanent blindness to death from sepsis — a systemic infection caused by bacteria entering the bloodstream.
| Injury Category | Documented Cases | Source |
|---|---|---|
| Total CRPA Infections Identified | 81 across 18 states | CDC Investigation |
| Deaths Attributed to Contamination | At least 4 confirmed | CDC/FDA Joint Investigation |
| Enucleations (Surgical Eye Removal) | 4 confirmed | CDC/FDA Joint Investigation |
| Vision Loss Cases | Multiple reported | FDA Adverse Event Reports |
| Corneal Ulcers / Severe Infections | Numerous reported | FDA MedWatch Database |
Thomas B. Harrison is a personal injury legal consultant with extensive experience connecting injury victims with qualified attorneys across the United States. He specializes in helping people understand when they need legal representation and how to find the right personal injury attorney for their specific situation. Thomas is not an attorney and the information he provides is for educational purposes only.